-+ 0.00%
-+ 0.00%
-+ 0.00%

Thermo Fisher Scientific (TMO) Stock Looks Priced At A Premium To Fair Value

Simply Wall St·11/20/2026 14:08:59
Listen to the news

Thermo Fisher Scientific has rewarded long term holders with a solid multi year gain, which naturally raises the question of whether the current share price lines up with the cash it is expected to generate. Recent product launches and its role in key life sciences markets give the story momentum, but the real issue for you as an investor is what those developments mean for future cash flows.

  • Over the past 3 years, Thermo Fisher Scientific has returned 42.6%. A meaningful part of the investment case now hinges on whether that share price performance is backed by the business's cash generation.
  • The launch of the Gibco VaxEvo CD 293 Medium for adenovirus vaccine production, together with Thermo Fisher Scientific's role in clinical trial logistics and gene therapy tools, can influence expectations for how quickly and reliably new projects convert into cash and what ongoing investment they may require.
  • What if you looked at Thermo Fisher Scientific through its earnings instead? See why Thermo Fisher Scientific's 36.1x P/E tells a different valuation story.

The stock's next move may depend on whether Thermo Fisher Scientific's current valuation is properly supported by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

If you want extra context on Thermo Fisher Scientific's story around its cash flows and valuation, it can help to compare it with other companies screened for 35 high quality undervalued stocks.

Does Thermo Fisher Scientific Look Pricey on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Thermo Fisher Scientific’s future free cash flows could be worth in today’s money. Latest twelve month free cash flow sits at about $7.7b, and the projections used in the DCF assume those cash flows grow from that base rather than shrink.

On those assumptions, the DCF estimate comes out meaningfully below the current share price of $688.75. This implies investors today are paying a premium for Thermo Fisher Scientific’s position in life sciences and tools. The launch of the Gibco VaxEvo CD 293 Medium helps explain why the market is willing to pay up, since it reinforces the story that new products and platforms can extend that cash flow stream. Find out what Thermo Fisher Scientific could be worth using our Discounted Cash Flow (DCF) estimate.

The Thermo Fisher Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Thermo Fisher Scientific valuation puzzle leaves off. They spell out which future growth, margin and earnings paths would need to play out for the stock to be worth materially more or less than today’s price, and they sit on Simply Wall St's Community page. Each one focuses on the assumptions that sit behind a fair value view rather than a single multiple or model point estimate, so you can later compare those starting premises with the actual results as they come through.

Bulls see Thermo Fisher Scientific as having more to give, while bears think expectations already price in most of the good news.

Bull case: 8% undervalued

The analyst consensus Narrative on Simply Wall St sees room for the Thermo Fisher Scientific story to keep compounding if execution holds.

"Ongoing portfolio-deepening M&A, including the recent Clario and Solventum filtration deals that are tracking ahead of initial assumptions, is set to tilt the mix toward higher value segments..."

Discover why this Narrative puts Thermo Fisher Scientific at 8% undervalued.

Bear case: roughly fairly valued

The bearish analyst Narrative on Simply Wall St argues that recent wins still leave limited room if any part of the Thermo Fisher Scientific setup stumbles.

"The current valuation reflects expectations that Thermo Fisher Scientific will continue to deliver high single digit earnings growth and participate in long term outsourcing, bioprocessing, and AI driven analytics opportunities..."

Explore why this Narrative puts Thermo Fisher Scientific at roughly fairly valued.

Thermo Fisher Scientific’s valuation story is only half the picture

Price and cash flows tell you a lot about Thermo Fisher Scientific, but the real puzzle is what the latest risk checks are quietly flagging for closer inspection. Take a closer look at 2 warning signs before settling on a valuation.